基石藥業-B(02616.HK)約2.28億元投資違反公司投資政策
基石藥業-B(02616.HK)公布,於2021年7月14日,公司透過CStone Pharm (HK)訂立本金額約2.28億元的投資事項。根據董事會及審核委員會意見,投資事項有效並可由及針對CStone Pharm (HK)執行,但違反公司投資政策。
經考慮上述事件並為防止未來發生類似事件,於調查後,董事會已成立投資委員會以協助董事會處理投資相關事宜,並採取補救行動。
董事會決議,自2016年11月起擔任執行董事並自2018年8月起擔任主席的首席執行官應終止擔任主席,自公告日期起生效並留任董事會執行董事。為嚴格遵守上市規則下首席執行官及主席應有區分的要求,李偉自2015年12月起擔任非執行董事,應出任主席,自公告日期起生效。
公司已成立投資委員會,旨在協助董事會包括批准投資策略、制定投資政策及程序、批准投資決策和檢討投資表現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.